New data boosts Novo against Sanofi in insulin-market fight

Carly Helfand Novo Nordisk has some new data in hand that could help a safety advantage make its way onto the label of new drug Tresiba–and win it points against heavyweight ...

Sanofi and Regeneron likely to cough up royalties to end Amgen’s PCSK9 patent suit: Analyst

Tracy Staton One of the hottest races for market share in pharma these days is between Amgen's cholesterol-fighter Repatha and Praluent, from Sanofi and Regeneron. They're apparently ...

BMS, Lilly, Sanofi and Novartis top Big Pharma’s growth fortunes for next decade: Analysts

Tracy Staton Predicting the future–particularly when it comes to Big Pharma's prospects for growth and earnings–is a favorite pastime among industry-watchers. Even better ...

#JPM16 Roundup: What you need to know on Pfizer, Sanofi and more

Carly Helfand SAN FRANCISCO–On Monday, we brought you the lowdown from the J.P. Morgan Healthcare Conference, with company presentations from pharma giants including Novartis ...

Sanofi drops option, inks $750M R&D collaboration with Warp Drive Bio

John Carroll Three years after Sanofi signed on to back Cambridge, MA-based Warp Drive Bio, taking an option to buy, the pharma giant has stepped back up to retool the terms, opting ...

Sanofi commits €400M to another cancer R&D pact, this time with Innate Pharma

John Carroll Less than a year after Sanofi downsized its cancer drug R&D operations, the pharma giant has struck back-to-back deals to launch new immuno-oncology drug programs, ...

Sanofi gets first approval for long-anticipated vaccine against dengue fever

Eric Palmer After two decades and $ 1.65 billion in research, French drugmaker Sanofi has gotten an approval for the world's first vaccine against the sometimes deadly dengue fever, ...

Lilly, Sanofi, Novo among many pharma players to throw off big price gains in H1

Eric Palmer The first half of the year has provided a good ride for Big Pharma and its investors with indices up in the U.S. and Europe. Even Japanese drugmakers avoided the side effects ...

With solid Q2, Sanofi CEO says M&A could be part of growth strategy

Eric Palmer Sanofi's new CEO, Olivier Brandicourt, has a new company structure he is trotting out, a new potentially hot cholesterol-lowering drug to launch and now is able to take ...

Sanofi and Regeneron line up for second place in EU cardio race

Damian Garde Sanofi and Regeneron may be on pace to win the first U.S. approval for a new type of cholesterol treatment, but the pair trails rival Amgen in Europe in a race to make ...

UPDATED: Sanofi and Regeneron pick up a blockbuster cardio approval–with a catch

Damian Garde Sanofi and Regeneron won an expected FDA approval for the first of a new class of cholesterol drugs expected to alter the landscape in cardiology, but regulators stopped ...

Merck cancer drugs and Sanofi, Amgen cardio meds have formularies on high alert

Eric Palmer U.S. drug payers have been able to beat back high prices for some COPD and diabetes drugs, much to the chagrin of GlaxoSmithKline and Sanofi. But several new categories ...
Page 1 of 1012345...10...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS